Adenoviral-mediated overexpression of human equilibrative nucleoside transporter 1 (hENT1) enhances gemcitabine response in human pancreatic cancer

Biochemical Pharmacology

Volumn 76, Issue 3, 2008, Pages 322-329

  Pérez Torras, Sandra ^a   García Manteiga, José ^a   Mercadé, Elena ^a   Casado, F Javier ^a,b   Carbó, Neus ^a   Pastor Anglada, Marçal ^a,b   Mazo, Adela ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adenovirus; hENT1; Nucleoside analogues; Nucleoside transport; Pancreatic cancer

Indexed keywords

AD5CMV HENT1 COMPLEX; ADENOVIRUS VECTOR; DEOXYCYTIDINE KINASE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; RIBONUCLEOTIDE REDUCTASE;

ADENOVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL MEMBRANE; CONTROLLED STUDY; CYTOTOXICITY; DRUG SENSITIVITY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NUCLEIC ACID METABOLISM; NUCLEOSIDE TRANSPORT; PANCREAS CANCER; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS RECOMBINANT; WESTERN BLOTTING;

ADENOCARCINOMA; ADENOVIRIDAE; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CELL CYCLE; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FEMALE; GENETIC VECTORS; HUMANS; INJECTIONS, INTRALESIONAL; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PANCREATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; RECOMBINANT FUSION PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; URIDINE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 46649083576     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2008.05.011     Document Type: Article

References (34)

1. Pastor-Anglada M., Felipe A., and Casado F.J. Transport and mode of action of nucleoside derivatives used in chemical and antiviral therapies. Trends Pharmacol Sci 19 (1998) 424-430
2. Ritzel M.W., Yao S.Y., Huang M.Y., Elliott J.F., Cass C.E., and Young J.D. Molecular cloning and functional expression of cDNAs encoding a human Na+-nucleoside cotransporter (hCNT1). Am J Physiol 272 (1997) C707-C714
3. Griffiths M., Beaumont N., Yao S.Y., Sundaram M., Boumah C.E., Davies A., et al. Cloning of a human nucleoside transporter implicated in the cellular uptake of adenosine and chemotherapeutic drugs. Nat Med 3 (1997) 89-93
4. Gray J.H., Owen R.P., and Giacomini K.M. The concentrative nucleoside transporter family, SLC28. Pflugers Arch 447 (2004) 728-734
5. Goh L.B., Mack P., and Lee C.W. Nitrobenzylthioinosine-binding protein overexpression in human breast, liver, stomach and colorectal tumour tissues. Anticancer Res 15 (1995) 2575-2579
6. del Santo B., Valdes R., Mata J., Felipe A., Casado F.J., and Pastor-Anglada M. Differential expression and regulation of nucleoside transport systems in rat liver parenchymal and hepatoma cells. Hepatology 28 (1998) 1504-1511
7. Dragan Y., Valdes R., Gomez-Angelats M., Felipe A., Javier Casado F., Pitot H., et al. Selective loss of nucleoside carrier expression in rat hepatocarcinomas. Hepatology 32 (2000) 239-246
8. Pennycooke M., Chaudary N., Shuralyova I., Zhang Y., and Coe I.R. Differential expression of human nucleoside transporters in normal and tumor tissue. Biochem Biophys Res Commun 280 (2001) 951-959
9. Mackey J.R., Jennings L.L., Clarke M.L., Santos C.L., Dabbagh L., Vsianska M., et al. Immunohistochemical variation of human equilibrative nucleoside transporter 1 protein in primary breast cancers. Clin Cancer Res 8 (2002) 110-116
10. Farre X., Guillen-Gomez E., Sanchez L., Hardisson D., Plaza Y., Lloberas J., et al. Expression of the nucleoside-derived drug transporters hCNT1, hENT1 and hENT2 in gynecologic tumors. Int J Cancer 112 (2004) 959-966
11. Molina-Arcas M., Moreno-Bueno G., Cano-Soldado P., Hernandez-Vargas H., Casado F.J., Palacios J., et al. Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5′-DFUR in breast cancer MCF7 cells. Biochem Pharmacol 72 (2006) 1646-1656
12. Aran J.M., and Plagemann P.G. High-affinity, equilibrative nucleoside transporter of pig kidney cell line (PK-15). Biochim Biophys Acta 1108 (1992) 67-74
13. Sarkar M., Han T., Damaraju V., Carpenter P., Cass C.E., and Agarwal R.P. Cytosine arabinoside affects multiple cellular factors and induces drug resistance in human lymphoid cells. Biochem Pharmacol 70 (2005) 426-432
14. Mackey J.R., Mani R.S., Selner M., Mowles D., Young J.D., Belt J.A., et al. Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. Cancer Res 58 (1998) 4349-4357
15. Achiwa H., Oguri T., Sato S., Maeda H., Niimi T., and Ueda R. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer. Cancer Sci 95 (2004) 753-757
16. Mori R., Ishikawa T., Ichikawa Y., Taniguchi K., Matsuyama R., Ueda M., et al. Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17 (2007) 1201-1205
17. Huang Y., Anderle P., Bussey K.J., Barbacioru C., Shankavaram U., Dai Z., et al. Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64 (2004) 4294-4301
18. Rauchwerger D.R., Firby P.S., Hedley D.W., and Moore M.J. Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity. Cancer Res 60 (2000) 6075-6079
19. Lu X., Gong S., Monks A., Zaharevitz D., and Moscow J.A. Correlation of nucleoside and nucleobase transporter gene expression with antimetabolite drug cytotoxicity. J Exp Ther Oncol 2 (2002) 200-212
20. Galmarini C.M., Thomas X., Calvo F., Rousselot P., Jafaari A.E., Cros E., et al. Potential mechanisms of resistance to cytarabine in AML patients. Leuk Res 26 (2002) 621-629
21. Stam R.W., den Boer M.L., Meijerink J.P., Ebus M.E., Peters G.J., Noordhuis P., et al. Differential mRNA expression of Ara-C-metabolizing enzymes explains Ara-C sensitivity in MLL gene-rearranged infant acute lymphoblastic leukemia. Blood 101 (2003) 1270-1276
22. Molina-Arcas M., Bellosillo B., Casado F.J., Montserrat E., Gil J., Colomer D., et al. Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 101 (2003) 2328-2334
23. Molina-Arcas M., Marce S., Villamor N., Huber-Ruano I., Casado F.J., Bellosillo B., et al. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells. Leukemia 19 (2005) 64-68
24. Spratlin J., Sangha R., Glubrecht D., Dabbagh L., Young J.D., Dumontet C., et al. The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10 (2004) 6956-6961
25. Giovannetti E., Del Tacca M., Mey V., Funel N., Nannizzi S., Ricci S., et al. Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66 (2006) 3928-3935
26. Oguri T., Achiwa H., Muramatsu H., Ozasa H., Sato S., Shimizu S., et al. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer. Cancer Lett 256 (2007) 112-119
27. Pastor-Anglada M., and Casado F.J. Nucleoside transport into cells. In: Peters G.J. (Ed). Cancer drug discovery and development: deoxynucleoside analogs in cancer therapy (2006), Humana Press Inc., Totowa, NJ 1-28
28. Galmarini C.M., Mackey J.R., and Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 15 (2001) 875-890
29. Fernandez-Veledo S., Valdes R., Wallenius V., Casado F.J., and Pastor-Anglada M. Up-regulation of the high-affinity pyrimidine-preferring nucleoside transporter concentrative nucleoside transporter 1 by tumor necrosis factor-alpha and interleukin-6 in liver parenchymal cells. J Hepatol 41 (2004) 538-544
30. Soler C., Garcia-Manteiga J., Valdes R., Xaus J., Comalada M., Casado F.J., et al. Macrophages require different nucleoside transport systems for proliferation and activation. FASEB J 15 (2001) 1979-1988
31. Pressacco J., Mitrovski B., Erlichman C., and Hedley D.W. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 55 (1995) 1505-1508
32. Pressacco J., Wiley J.S., Jamieson G.P., Erlichman C., and Hedley D.W. Modulation of the equilibrative nucleoside transporter by inhibitors of DNA synthesis. Br J Cancer 72 (1995) 939-942
33. Nakano Y., Tanno S., Koizumi K., Nishikawa T., Nakamura K., Minoguchi M., et al. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells. Br J Cancer 96 (2007) 457-463
34. Gloeckner-Hofmann K., Guillen-Gomez E., Schmidtgen C., Porstmann R., Ziegler R., Stoss O., et al. Expression of the high-affinity fluoropyrimidine-preferring nucleoside transporter hCNT1 correlates with decreased disease-free survival in breast cancer. Oncology 70 (2006) 238-244